Hwang, Jimmy
https://orcid.org/0000-0001-8654-7071
Mayo Clinic
University of California, San Francisco
Citations 1
A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies.
Vidula, Neelima , Goga, Andrei , Hwang, Jimmy , Liu, Minetta C. , Nanda, Rita , Pohlmann, Paula R. , Storniolo, Anna Maria , Brufsky, Adam , Brufsky, Adam M , Park, Ben Ho , Abramson, Vandana G. , Rugo, Hope S. , Pohlmann, Paula
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS1113-TPS1113
